Kenvue (NYSE:KVUE) Downgraded to “Hold” Rating by Zacks Research

Zacks Research cut shares of Kenvue (NYSE:KVUE) from a strong-buy rating to a hold rating in a report released on Tuesday morning,Zacks.com reports.

A number of other brokerages have also recently issued reports on KVUE. UBS Group decreased their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Weiss Ratings upgraded Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, June 15th. Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, April 15th. Finally, Barclays dropped their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 14th. Three research analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat, Kenvue currently has an average rating of “Hold” and an average target price of $19.33.

Kenvue Stock Down 2.5%

Shares of NYSE KVUE opened at $19.28 on Tuesday. The stock has a market capitalization of $37.01 billion, a P/E ratio of 22.68, a PEG ratio of 1.50 and a beta of 0.47. The stock’s fifty day moving average is $17.98 and its 200 day moving average is $17.76. Kenvue has a 52 week low of $14.02 and a 52 week high of $22.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. During the same period in the prior year, the company posted $0.24 earnings per share. The business’s revenue for the quarter was up 4.5% on a year-over-year basis. Sell-side analysts forecast that Kenvue will post 1.16 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a dividend of $0.2075 per share. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.3%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insiders Place Their Bets

In other Kenvue news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.59% of the stock is owned by insiders.

Institutional Trading of Kenvue

Several institutional investors have recently modified their holdings of the business. Physician Wealth Advisors Inc. lifted its holdings in Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC bought a new position in shares of Kenvue during the fourth quarter worth about $26,000. MV Capital Management Inc. bought a new position in shares of Kenvue during the fourth quarter worth about $28,000. CoreCap Advisors LLC lifted its stake in shares of Kenvue by 64.9% in the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after acquiring an additional 591 shares during the period. Finally, Reflection Asset Management bought a new stake in Kenvue in the fourth quarter valued at approximately $32,000. Institutional investors own 97.64% of the company’s stock.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.